The health sector posted modest gains on Tuesday, with a handful of drug developers such as Eli Lilly, Biogen and Merck outperforming the broader index.
Hims and Hers Health inked a deal to acquire European health platform Zava. Hims stock fell.
Roche said a drug combination, Tecentriq combined with lurbinectedin, shows survival benefits for patients with extensive-stage small-cell lung cancer. The Swiss pharmaceutical company said that late-stage trials showed the combination led to a 46% reduction in the risk of the disease progressing or death, and 27% reduction in the risk of death. Roche shares fell in the European session.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 03, 2025 17:11 ET (21:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.